Cargando…
Inhibition of eNOS Partially Blunts the Beneficial Effects of Nebivolol on Angiotensin II-Induced Signaling in H9c2 Cardiomyoblasts
We have recently illustrated that nebivolol can inhibit angiotensin II (Ang II)-mediated signaling in cardiomyoblasts; however, to date, the detailed mechanism for the beneficial effects of nebivolol has not been studied. Here, we investigated whether the inhibition of NO bioavailability by blocking...
Autores principales: | Gul, Rukhsana, Alsalman, Nouf, Alfadda, Assim A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164031/ https://www.ncbi.nlm.nih.gov/pubmed/35678673 http://dx.doi.org/10.3390/cimb44050144 |
Ejemplares similares
-
Comparison of the Protective Effects of Nebivolol and Metoprolol against LPS-Induced Injury in H9c2 Cardiomyoblasts
por: Gul, Rukhsana, et al.
Publicado: (2023) -
Protective Effects of Nanoceria against Mitochondrial Dysfunction and Angiotensin II-Induced Hypertrophy in H9c2 Cardiomyoblasts
por: Gul, Rukhsana, et al.
Publicado: (2023) -
Regulation of cardiac miR-208a, an inducer of obesity, by Rapamycin and Nebivolol
por: Gul, Rukhsana, et al.
Publicado: (2015) -
Renin-angiotensin system at the interface of COVID-19 infection
por: Gul, Rukhsana, et al.
Publicado: (2021) -
Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS
por: Yu, Jing, et al.
Publicado: (2021)